Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

Rhea-AI Summary

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company, announced that its CEO, Kenneth A. Berlin, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. Berlin's presentation is scheduled for Wednesday, September 2, at 3:40 PM ET. Advaxis focuses on developing proprietary Lm-based immunotherapy products using bioengineered Listeria monocytogenes to stimulate anti-tumor T cell immunity. For more details, interested parties can access the webcast via a provided link.

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 – 4, 2020.

Presentation Information:
Date: Wednesday, September 2^nd                        
Time: 3:40 pm ET                          
Webcast: https://www.webcaster4.com/Webcast/Page/2019/36689                 

About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564

FAQ

When will Advaxis present at the LD Micro 500 Virtual Conference?

Advaxis will present on Wednesday, September 2, 2020, at 3:40 PM ET.

What is the focus of Advaxis, Inc.?

Advaxis, Inc. focuses on the development and commercialization of immunotherapy products, particularly using Lm-based antigen delivery.

How can I access the Advaxis presentation webcast?

You can access the Advaxis presentation webcast at the link provided in the press release.

Who is the CEO of Advaxis, Inc.?

Kenneth A. Berlin is the President and CEO of Advaxis, Inc.

What is unique about Advaxis's immunotherapy products?

Advaxis utilizes live attenuated Listeria monocytogenes bioengineered to enhance anti-tumor T cell immunity through a single immunotherapy approach.